COPENHAGEN, Denmark, November 13, 2020 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) publishes corrected information about the following transactions of the company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such.
1. | Details of the person discharging managerial responsibilities/person closely associated | ||
a) | Name | Anu Helena Kerns | |
2. | Reason for the notification | ||
a) | Position/status
|
Executive Vice President People & Organization of Bavarian Nordic A/S | |
b) | Initial notification/Amendment | Amendment to notification of November 11, 2020. The volume of granted warrants has been adjusted. | |
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Bavarian Nordic A/S | |
b) | LEI | 2138006JCDVYIN6INP51 | |
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument
Identification code |
Warrants
DK0015998017 |
|
b) | Nature of the transaction | Grant | |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
DKK 0.00 | 38,756 | ||
d) | Aggregated information
|
38,756 |
|
e) | Date of the transaction | 2020-11-11 | |
f) | Place of the transaction | Outside a trading venue |
About Bavarian Nordic
Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacture and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Strategic National Stockpile of a non-replicating smallpox vaccine, which has been approved by the FDA under the trade name JYNNEOS®, also for the protection against monkeypox. The vaccine is approved as a smallpox vaccine in Europe under the trade name IMVANEX® and in Canada under the trade name IMVAMUNE®. Our commercial product portfolio furthermore contains the market-leading vaccine Rabipur®/RabAvert® against rabies and Encepur® against tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an Ebola vaccine, MVABEA®, which is licensed to Janssen. For more information visit www.bavarian-nordic.com.
Contacts
Europe: Rolf Sass Sørensen, Vice President Investor Relations, Tel: +45 61 77 47 43
US: Graham Morrell, Paddock Circle Advisors, graham@paddockcircle.com, Tel: +1 781 686 9600
Company Announcement no. 49 / 2020
Attachment
Toronto, Ontario--(Newsfile Corp. - June 27, 2024) - Neural Therapeutics Inc. ("Neural" or the "Company"),…
Charlotte, North Carolina--(Newsfile Corp. - June 27, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE…
Ranking includes factors such as diversity, culture, work-life balance, career opportunities CHICAGO, June 27, 2024…
All caregivers in the state can access free resources at home PIERRE, S.D., June 27,…
Infusyn Therapeutics will manufacture and supply the Prometra II pump currently serving the Pain and…
Training Supports Individuals and Peer Support Networks, Promoting Culture of Wellness to Save Lives OKLAHOMA…